Altimmune, Inc. (NASDAQ:ALT – Get Free Report)’s stock price was up 9.2% on Friday . The company traded as high as $3.22 and last traded at $3.22. 1,880,626 shares were traded during mid-day trading, a decline of 57% from the average session volume of 4,360,463 shares. The stock had previously closed at $2.95.
Analyst Ratings Changes
ALT has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Wednesday, June 24th. Citizens Jmp cut their target price on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research report on Thursday, May 14th. Wall Street Zen raised Altimmune from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Leerink Partners began coverage on Altimmune in a research report on Monday, June 22nd. They set an “outperform” rating and a $10.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.33.
Get Our Latest Stock Report on ALT
Altimmune Price Performance
Altimmune (NASDAQ:ALT – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Altimmune had a negative return on equity of 31.41% and a negative net margin of 214,860.98%. On average, sell-side analysts predict that Altimmune, Inc. will post -0.58 earnings per share for the current year.
Institutional Trading of Altimmune
A number of hedge funds have recently bought and sold shares of ALT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after acquiring an additional 2,241 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Altimmune during the first quarter valued at $50,000. Envestnet Asset Management Inc. grew its stake in Altimmune by 48.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 32,908 shares of the company’s stock valued at $127,000 after acquiring an additional 10,671 shares in the last quarter. Creative Planning grew its position in Altimmune by 30.2% during the second quarter. Creative Planning now owns 41,164 shares of the company’s stock valued at $159,000 after purchasing an additional 9,558 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Altimmune by 7.0% during the 2nd quarter. Rhumbline Advisers now owns 113,981 shares of the company’s stock valued at $441,000 after acquiring an additional 7,462 shares in the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.
About Altimmune
Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.
Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.
Featured Stories
- Five stocks we like better than Altimmune
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
